Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox vs Venesection in Hemochromatosis and MDS
NCT01892644Phase 2Withdrawn
- Sponsor
- Haukeland University Hospital
- Start
- May 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of deferasirox in hemochromatosis (HH) and iron overload (4 arms), sponsored by Haukeland University Hospital. Primary endpoints: Liver Iron Concentration at 12 months, Heart Iron Concentration at 12 months and 1 more. Planned start May 2013; status: withdrawn.
02
Drugs
deferasirox
03
Conditions
hemochromatosis (HH)iron overload
Beyond the preview
Go deeper on NCT01892644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01892644.